Skip to main content
Clinical Trials/NCT00170313
NCT00170313TerminatedPhase 4

Conducted AF-Response Study (Study to Evaluate the Conducted AF-Response-Algorithm in Patients Suffering From Heart Failure and Atrial Fibrillation Treated With InSync III Marquis)

Medtronic Cardiac Rhythm and Heart Failure7 sites in 1 country100 target enrollmentStarted: December 1, 2003Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Terminated
Sponsor
Enrollment
100
Locations
7
Primary Endpoint
Amount of biventricular pacing in ON-group compared to OFF-group

Study Overview

Brief Summary

The Medtronic InSync III Marquis Cardiac Resynchronization Therapy Defibrillator (CRT-D)-System (implantable cardioverter-defibrillator with biventricular stimulation for cardiac resynchronization) is equipped with the "Conducted-Atrial Fibrillation (AF)-Response-Algorithm (CAFR)". This algorithm is designed to maximize biventricular stimulation and thus the amount of cardiac resynchronization when atrial fibrillation occurs. The goal of the study is the evaluation of the effect of the CAFR in CRT-patients suffering from atrial fibrillation by quantification of the increase of biventricular pacing during atrial fibrillation caused by CAFR as well as the influence of the CAFR on the ventricular heart rate.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Implant of a Medtronic InSync III Marquis (7279) or later system with Conducted AF-Response

Exclusion Criteria

  • •Medical reasons that are adverse to participation in the study and compliance by the patient
  • •Patients who are enrolled in another study or plan to be enrolled into another study
  • •Pregnant patients or patients who are possibly pregnant due to an unreliable form of contraception

Arms & Interventions

Conducted AF-Response Algorithm (CAFR) On

Experimental

CAFR: On

  • Level medium
  • Max. Rate: 110ppm VSR: Off

Intervention: Conducted AF-Response Algorithm (CAFR) On (Device)

Conducted AF-Response Algorithm (CAFR) Off

Active Comparator

CAFR: Off VSR: Off

Intervention: Conducted AF-Response Algorithm (CAFR) Off (Device)

Outcomes

Primary Outcomes

Amount of biventricular pacing in ON-group compared to OFF-group

Time Frame: 1 month post-implant to 12 months post-implant

Secondary Outcomes

  • Characterization of the heart failure (HF)-patient population by means of: left ventricular end systolic diameter (LVESD [mm])(Implant to 12 months post-implant)
  • Influence of the conducted AF response algorithm on the ventricular heart rate during atrial fibrillation(1 month post-implant to 12 months post-implant)
  • Characterization of the heart failure (HF)-patient population by means of: left atrial end diastolic diameter (LAEDD [mm])](Implant to 12 months post-implant)
  • Amount of hospitalizations due to heart failure (amount and duration in days)(Implant to 12 months post-implant)
  • Occurrence and evaluation of rhythm disturbances: atrial arrhythmias (atrial tachyarrhythmia [AT]/AF episodes [h/day])(Implant to 12 months post-implant)
  • Occurrence and evaluation of rhythm disturbances: ventricular arrhythmias(Implant to 12 months post-implant)
  • Characterization of the heart failure (HF)-patient population by means of: echocardiography [left ventricular ejection fraction (LVEF [%])(Implant to 12 months post-implant)
  • Characterization of the heart failure (HF)-patient population by means of: left ventricular end diastolic diameter (LVEDD [mm])(Implant to 12 months post-implant)
  • Amount of patients who will be free from AF during the study(Implant to 12 months post-implant)
  • Characterization of the heart failure (HF)-patient population by means of: New York Heart Association (NYHA) classification(Implant to 12 months post-implant)
  • Characterization of the heart failure (HF)-patient population by means of: 6-minute walk test(Implant to 12 months post-implant)

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials